S&P Global, Berkshire Hathaway, CME Group And A Health Care Stock: CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners named Berkshire Hathaway Inc. BRK as his final trade ahead of its quarterly earnings report on Saturday.

On April 25, UBS analyst Brian Meredith maintained a Buy rating for Berkshire Hathaway and raised the price target from $557 to $606.

Stephen L. Weiss of Short Hills Capital Partners picked Vertex Pharmaceuticals Incorporated VRTX as his final trade.

Lending support to his choice, Cantor Fitzgerald analyst Carter Gould, on April 22, initiated coverage of Vertex Pharmaceuticals with an Overweight rating and announced a price target of $535.

Don't forget to check out our premarket coverage here

Karen Firestone of Aureus Asset Management said S&P Global Inc. SPGI reported a great quarter.

S&P Global reported quarterly adjusted earnings per share of $4.37 on Tuesday, beating the analyst consensus estimate of $4.19 per share. Quarterly sales of $3.78 billion (up 8% year over year) outpaced the street view of $3.70 billion. Revenue from subscription products increased 7%.

Earn 7.2% — No Matter What the Fed Does

Markets expect rate cuts — but your earnings don’t have to suffer. Lock in 7.2% until 2028 from ten individual bonds.

Joseph M. Terranova of Virtus Investment Partners said he likes CME Group Inc. CME.

On the earnings front, CME Group posted first-quarter adjusted earnings of $2.80 per share on April 23, beating market estimates of $2.79 per share. The company's quarterly sales came in at $1.60 billion versus expectations of $1.64 billion.

Price Action:

Berkshire Hathaway shares fell 0.3% to close at $533.25 on Wednesday.
Vertex Pharmaceuticals gained 1.2% to close at $509.50 during Wednesday's session.
S&P Global gained 1.7% to close at $500.05 on Wednesday.
CME Group shares climbed 1.7% to settle at $277.08 during the session.

Check This Out: